Search Results Label

Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.

https://www.seqirus.us/expertise/influenza/pandemic-response-solutions

Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.seqirus.us/expertise

Seqirus Presents New Data at ESWI 2020 Demonstrating Safety and Immunogenicity of Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine

https://www.seqirus.us/news/seqirus-presents-new-data-at-eswi-2020-demonstrating-safety-and-immunogenicity

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news/seqirus-announces-us-fda-approval-of-pandemic-influenza-vaccine

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news

The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic

https://www.seqirus.us/news/first-shipment-2021-22

New Phase 3 Clinical Data Supporting Use of Cell-Based Seasonal Influenza Vaccine in Children Six Months Through <4 Years of Age

https://www.seqirus.us/news/data-supports-cell-based-flu-vaccine-in-children

Seqirus announced today that the accelerated development of cell-based manufacturing technology at its manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase in seasonal influenza vaccine output in just two years, strengthening the United States’ capacity to respond to pandemic threats.

https://www.seqirus.us/news/seqirus-announces-major-advances-in-pandemic-preparedness

New Seqirus Data Published in Vaccines Highlight Effectiveness and Economic Benefit of Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) in the 2018/19 U.S. Influenza Season

https://www.seqirus.us/news/new-seqirus-data-published-in-vaccines-highlight-effectiveness

Seqirus Announces U.S. FDA Approval of Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and Older

https://www.seqirus.us/news/seqirus-announces-us-fda-approval-of-expanded-age-indication